Kiltearn Partners LLP Sells 5,100 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Kiltearn Partners LLP cut its stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 9.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,700 shares of the company's stock after selling 5,100 shares during the period. HCA Healthcare accounts for approximately 2.5% of Kiltearn Partners LLP's investment portfolio, making the stock its 17th largest holding. Kiltearn Partners LLP's holdings in HCA Healthcare were worth $14,917,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in HCA Healthcare during the 4th quarter valued at about $840,286,000. Royal London Asset Management Ltd. grew its holdings in HCA Healthcare by 62.0% in the 4th quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company's stock worth $450,461,000 after buying an additional 574,239 shares in the last quarter. Principal Financial Group Inc. raised its stake in HCA Healthcare by 120.1% during the 4th quarter. Principal Financial Group Inc. now owns 873,775 shares of the company's stock valued at $262,264,000 after acquiring an additional 476,756 shares in the last quarter. Meritage Group LP bought a new position in shares of HCA Healthcare in the third quarter worth $150,548,000. Finally, Raymond James Financial Inc. bought a new stake in shares of HCA Healthcare during the fourth quarter valued at about $74,121,000. Institutional investors and hedge funds own 62.73% of the company's stock.

Insider Buying and Selling

In other news, SVP Jennifer Berres sold 9,533 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the transaction, the senior vice president now owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Remove Ads

HCA Healthcare Stock Up 0.4 %

NYSE:HCA traded up $1.51 during trading hours on Tuesday, hitting $347.06. 280,237 shares of the company's stock traded hands, compared to its average volume of 1,643,080. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.97 and a current ratio of 1.08. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14. The stock's fifty day moving average price is $325.24 and its two-hundred day moving average price is $340.60. The firm has a market cap of $85.45 billion, a P/E ratio of 15.80, a P/E/G ratio of 1.10 and a beta of 1.68.

HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same period last year, the firm posted $5.90 EPS. On average, research analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 17th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.83%. This is a positive change from HCA Healthcare's previous quarterly dividend of $0.66. The ex-dividend date was Monday, March 17th. HCA Healthcare's payout ratio is currently 13.11%.

Analysts Set New Price Targets

A number of research firms have commented on HCA. Bank of America dropped their price target on shares of HCA Healthcare from $380.00 to $370.00 and set a "buy" rating on the stock in a research report on Monday, January 27th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $380.00 target price on shares of HCA Healthcare in a research report on Tuesday, December 17th. Barclays dropped their price objective on HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $405.00 target price on shares of HCA Healthcare in a report on Monday, January 27th. Finally, Truist Financial lowered their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $385.67.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.